Cookies on this site

Illustration of the inside of the intestine showing individual cells. © nobeastsofierce/Shutterstock.com

Researchers from the Simmons and Koohy Groups in the MRC Translational Immune Discovery Unit have identified potential pathways by which cancer treatment can cause colitis.

Checkpoint inhibitors (CPIs) are a type of cancer treatment that help the immune system fight cancer by removing some of its restraints. However, these treatments often cause debilitating side effects, including inflammation of the colon called colitis.

In this study, published in Cancer Cell, the research team used single cell and spatial analysis methods to paint a detailed picture of how these beneficial cancer therapies can sometimes lead to harmful side effects. This information could help to develop new ways to prevent and treat the side effects, without reducing the drugs’ cancer-fighting capabilities.

The study explored how CPIs lead to colitis by examining the behaviour and characteristics of T cells, a type of immune cell, in the colons of patients treated with these drugs. The researchers analysed both where the T cells were found within tissues and which genes were being expressed in the cells. They found that certain T cells in the gut still carried the CPI drug many weeks after it had been administered. These T cells behaved differently from other T cells and were found in distinct areas of the colon, suggesting that the CPI drugs modified their behaviour and possibly contributed to the development of colitis.

By mapping out where these T cells are located and how they interact with other cells, this study identified potential pathways through which CPIs cause colitis. This both improved understanding of the effect of the drug at the cellular level and provided a map of the inflammatory processes in the gut, including how drug-induced inflammation compares to other related conditions like inflammatory bowel disease.

Agne Antanaviciute, one of the co-first authors, said:

This work provides a foundation for developing strategies to mitigate these effects, improving patient care while continuing effective cancer treatment.

 Read the full paper here: https://www.cell.com/cancer-cell/fulltext/S1535-6108(24)00134-X

Recent stories

European grant to investigate how tissue ageing influences cancer development

An international team of researchers, including Professor Alison Simmons, has been awarded a €13.97 million Synergy Grant from the European Research Council (ERC) to investigate how ageing in tissues influences the development of cancer.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.